Study data presented at ACTRIMS 2026 suggests clinical MS onset may precede laboratory-confirmed primary EBV infection in some patients.
Genetically modified immune cells can offer precious additional time to patients with advanced multiple myeloma. However, these therapies lose their impact as the molecules on cancer cells that immune ...
Multiple myeloma was once viewed as an incurable diagnosis, but Ameet Patel, MD, of Florida Cancer Specialists & Research ...
In an interview, Saad Z. Usmani, MD, MBA, discussed the significance of phase 1 outcomes of gintemetostat therapy for patients with heavily pretreated multiple myeloma.
Experts discuss the importance of transitioning cancer care from academic centers to community practices, ensuring patient ...
Patients treated with ciltacabtagene autoleucel (cilta-cel; Carvykti) in the phase 3 CARTITUDE-4 trial (NCT04181827) achieved high rates of progression-free survival (PFS) at nearly 3 years, according ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results